{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T22:13:12Z","timestamp":1770415992021,"version":"3.49.0"},"reference-count":28,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2016,11,29]],"date-time":"2016-11-29T00:00:00Z","timestamp":1480377600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2017,2]]},"abstract":"\n Aims<\/jats:title>\n \n To explore the treatment outcomes in adult patients with type 2 diabetes (\n T2D<\/jats:styled-content>\n ) enrolled in the\n GetGoal<\/jats:styled-content>\n trials of lixisenatide (\n LIXI<\/jats:styled-content>\n ), and the predictive effects of baseline characteristics on outcomes.\n <\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n This study was a pooled analysis of patient\u2010level data from the\n LIXI GetGoal<\/jats:styled-content>\n studies comparing\n LIXI<\/jats:styled-content>\n and placebo. Patients were divided into baseline therapy groups: those receiving oral antidiabetes drugs (\n OADs<\/jats:styled-content>\n ) at baseline (n = 2760) or those receiving basal insulin at baseline (n = 1198).\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Compared with placebo,\n LIXI<\/jats:styled-content>\n treatment led to significantly greater reductions in glycated haemoglobin (\n HbA1c<\/jats:styled-content>\n ), and greater achievement of the composite endpoint of\n HbA1c<\/jats:styled-content>\n <7.0% (53 mmol\/mol) with no symptomatic hypoglycaemia and no weight gain in either the\n OAD<\/jats:styled-content>\n (34% vs 18%;\n P<\/jats:italic>\n < .0001) or the basal insulin groups (19% vs 10%;\n P<\/jats:italic>\n < .0001). Treatment with\n LIXI<\/jats:styled-content>\n was associated with a greater percentage of patients experiencing a symptomatic hypoglycaemic event compared with placebo in both the\n OAD<\/jats:styled-content>\n (5% vs 3%;\n P<\/jats:italic>\n = .0098) and basal insulin groups (27% vs 17%;\n P<\/jats:italic>\n < .0001). In assessing baseline factors that were predictors of treatment outcomes, only baseline\n HbA1c<\/jats:styled-content>\n and\n LIXI<\/jats:styled-content>\n treatment were strong predictors of outcomes in both the\n OAD<\/jats:styled-content>\n and basal insulin groups. No other baseline characteristic had such a large or consistent clinically relevant predictive effect across treatment outcomes.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n \n The results from this study show that irrespective of baseline characteristics,\n LIXI<\/jats:styled-content>\n treatment, as an add\u2010on to\n OAD<\/jats:styled-content>\n or basal insulin therapy, is effective in reducing\n HbA1c<\/jats:styled-content>\n and achieving composite endpoints.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/dom.12815","type":"journal-article","created":{"date-parts":[[2016,10,21]],"date-time":"2016-10-21T05:52:44Z","timestamp":1477029164000},"page":"275-283","source":"Crossref","is-referenced-by-count":16,"title":["Predictors of outcomes in patients with type 2 diabetes in the lixisenatide\n GetGoal<\/scp>\n clinical trials"],"prefix":"10.1111","volume":"19","author":[{"given":"Lawrence","family":"Blonde","sequence":"first","affiliation":[{"name":"Ochsner Diabetes Clinical Research Unit, Department of Endocrinology, Frank Riddick Diabetes Institute Ochsner Medical Center New Orleans Louisiana"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pavan","family":"Chava","sequence":"additional","affiliation":[{"name":"Ochsner Diabetes Clinical Research Unit, Department of Endocrinology, Frank Riddick Diabetes Institute Ochsner Medical Center New Orleans Louisiana"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terry","family":"Dex","sequence":"additional","affiliation":[{"name":"Sanofi US, Inc. Bridgewater New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jay","family":"Lin","sequence":"additional","affiliation":[{"name":"Novosys Health Green Brook New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena V.","family":"Nikonova","sequence":"additional","affiliation":[{"name":"Artech Information Systems LLC Morristown New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald M.","family":"Goldenberg","sequence":"additional","affiliation":[{"name":"LMC Diabetes and Endocrinology Thornhill Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,11,29]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.4158\/EP15672.GLSUPPL"},{"key":"e_1_2_6_3_1","unstructured":"GarberAJ AbrahamsonMJ BarzilayJI et al.Consensus statement by the American Association of Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm \u2013 2016 executive summary. 2016.https:\/\/www.aace.com\/sites\/all\/files\/diabetes\u2010algorithm\u2010executive\u2010summary.pdf. Accessed November 9 2016."},{"issue":"1","key":"e_1_2_6_4_1","article-title":"Standards of medical care in diabetes\u2013\u20132015","volume":"38","author":"American Diabetes Association","year":"2015","journal-title":"Diabetes Care"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-2441"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-2006"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-2454"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-1935"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2014.01.012"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12121"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-2462"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-2709"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/dme.12328"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.2541"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2012.01618.x"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-013-0489-3"},{"key":"e_1_2_6_17_1","first-page":"411","article-title":"Predictive factors associated with primary failure to exenatide and non goal attainment in patients with type 2 diabetes","volume":"67","author":"Preumont V","year":"2012","journal-title":"Acta Clin Belg"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/162718"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2014.11.015"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.12184"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1331\/JAPhA.2012.10217"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-014-0171-2"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.26.8.2370"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc06-2593"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2012.03699.x"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00030.2002"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1254\/jphs.09178FP"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12290"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.2647"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdom.12815","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.12815","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:20:36Z","timestamp":1761862836000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.12815"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,29]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["10.1111\/dom.12815"],"URL":"https:\/\/doi.org\/10.1111\/dom.12815","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,29]]}}}